Cargando…

Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity

Sorafenib and regorafenib are tyrosine kinase inhibitors that are used in the treatment of hepatocellular carcinoma and which have similar chemical structures and toxicity profiles. We herein report a case in which regorafenib treatment could be continued for 10 months and stable disease could be ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshioka, Naoki, Kuzuya, Teiji, Ito, Takanori, Ishizu, Yoji, Honda, Takashi, Ishikawa, Tetsuya, Ishigami, Masatoshi, Fujishiro, Mitsuhiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2019
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6815910/ https://www.ncbi.nlm.nih.gov/pubmed/31243207 http://dx.doi.org/10.2169/internalmedicine.2812-19

Ejemplares similares

Transient deterioration of albumin–bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study
por: Muto, Hisanori, et al.
Publicado: (2021)

Limitation of non-transplant treatment and proper timing for liver transplantation in patients with hepatocellular carcinoma considering long-term survival
por: Nomura, Aya, et al.
Publicado: (2020)

Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis
por: Yoshioka, Naoki, et al.
Publicado: (2020)

Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma
por: Kuzuya, Teiji, et al.
Publicado: (2015)

Effect of illness uncertainty on alanine transaminase levels and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease
por: Ozawa, Naoki, et al.
Publicado: (2022)

Changes in the gut microbiota after hepatitis C virus eradication
por: Honda, Takashi, et al.
Publicado: (2021)

Liver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct‐acting antivirals
por: Tachi, Yoshihiko, et al.
Publicado: (2017)

Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
por: Mizuno, Kazuyuki, et al.
Publicado: (2023)

Amino Acid Polymorphism in Hepatitis B Virus Associated With Functional Cure
por: Honda, Takashi, et al.
Publicado: (2021)

Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease
por: Yamamoto, Kenta, et al.
Publicado: (2022)

Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma
por: Inukai, Yosuke, et al.
Publicado: (2023)

Proteomic Analysis Reveals Changes in Tight Junctions in the Small Intestinal Epithelium of Mice Fed a High-Fat Diet
por: Muto, Hisanori, et al.
Publicado: (2023)

The albumin–bilirubin score as a predictor of outcomes in Japanese patients with PBC: an analysis using time-dependent ROC
por: Ito, Takanori, et al.
Publicado: (2020)

Antitumor effects of regorafenib and sorafenib in preclinical models of hepatocellular carcinoma
por: Kissel, Maria, et al.
Publicado: (2017)

Conditioned medium from stem cells derived from human exfoliated deciduous teeth ameliorates NASH via the Gut-Liver axis
por: Muto, Hisanori, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Effectiveness of nivolumab versus regorafenib in hepatocellular carcinoma patients who failed sorafenib treatment
por: Lee, Cheol-Hyung, et al.
Publicado: (2020)

Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma
por: Lee, I-Cheng, et al.
Publicado: (2022)

Inhibition of the PINK1-Parkin Pathway Enhances the Lethality of Sorafenib and Regorafenib in Hepatocellular Carcinoma
por: Zhang, Shun, et al.
Publicado: (2022)

Long-Term Regression after Discontinuation of Regorafenib Administered for Sorafenib-Refractory Hepatocellular Carcinoma
por: Bae, Heewon, et al.
Publicado: (2023)

Pipeline Esophagogastric Varices Secondary to Extrahepatic Portal Vein Obstruction Treated Endoscopically with the Assistance of Transileocolic Obliteration
por: Yokoyama, Shinya, et al.
Publicado: (2022)

Immunohistochemical staining for IMP3 in patients with duodenal papilla tumors: assessment of the potential for diagnosing endoscopic resectability and predicting prognosis
por: Tanaka, Hiroyuki, et al.
Publicado: (2021)

Successful Sequential Therapy Involving Regorafenib after Failure of Sorafenib in a Patient with Recurrent Hepatocellular Carcinoma after Liver Transplantation
por: Lee, Soon Kyu, et al.
Publicado: (2020)

Feasibility and usefulness of endoscopic ultrasonography-guided shear-wave measurement for assessment of autoimmune pancreatitis activity: a prospective exploratory study
por: Ohno, Eizaburo, et al.
Publicado: (2019)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib
por: Pelosof, Lorraine, et al.
Publicado: (2018)

Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib—A cost-effectiveness analysis
por: Shlomai, Amir, et al.
Publicado: (2018)

Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
por: Chen, Weibo, et al.
Publicado: (2019)

Regorafenib Versus Nivolumab After Sorafenib Failure: Real‐World Data in Patients With Hepatocellular Carcinoma
por: Choi, Won‐Mook, et al.
Publicado: (2020)

Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
por: Hong, Young Mi, et al.
Publicado: (2021)

A Successful Living Donor Liver Transplantation Using Hepatic Iron Deposition Graft Suspected by Magnetic Resonance Imaging
por: Kurata, Nobuhiko, et al.
Publicado: (2023)

Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib
por: Colombatto, Piero, et al.
Publicado: (2021)

Corrigendum to: Regorafenib reverses HGF‐induced sorafenib resistance by inhibiting epithelial‐mesenchymal transition in hepatocellular carcinoma
Publicado: (2022)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Two important factors affecting the prognosis of patients treated with sorafenib followed by regorafenib for advanced hepatocellular carcinoma
por: Li, Ning, et al.
Publicado: (2022)

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma
por: Tutusaus, Anna, et al.
Publicado: (2018)

Complete Response to the Sequential Treatment with Regorafenib Followed by PD-1 Inhibitor in a Sorafenib-Refractory Hepatocellular Carcinoma Patient
por: Zhang, Er-lei, et al.
Publicado: (2020)

On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma
por: Wang, Hung-Wei, et al.
Publicado: (2021)

Efficacy and Safety of TACE Combined with Regorafenib Plus PD-1 Inhibitor in the Treatment of Hepatocellular Carcinoma After Sorafenib Resistance
por: Zou, Xinhua, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_el05l5raoucja2o1a5djotq8bp